GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Cyclically Adjusted FCF per Share

Protalix BioTherapeutics (FRA:PBDA) Cyclically Adjusted FCF per Share : €-1.14 (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Protalix BioTherapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was €-0.065. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.14 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 9.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Protalix BioTherapeutics was 48.10% per year. The lowest was -6.20% per year. And the median was 8.50% per year.

As of today (2025-06-26), Protalix BioTherapeutics's current stock price is €1.20. Protalix BioTherapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €-1.14. Protalix BioTherapeutics's Cyclically Adjusted Price-to-FCF of today is .


Protalix BioTherapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Protalix BioTherapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Cyclically Adjusted FCF per Share Chart

Protalix BioTherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.70 -1.66 -1.83 -1.56 -1.22

Protalix BioTherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.48 -1.45 -1.04 -1.22 -1.14

Competitive Comparison of Protalix BioTherapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Protalix BioTherapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Protalix BioTherapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protalix BioTherapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.065/134.9266*134.9266
=-0.065

Current CPI (Mar. 2025) = 134.9266.

Protalix BioTherapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.531 100.684 -0.712
201509 -0.834 100.392 -1.121
201512 -0.358 99.792 -0.484
201603 -0.889 100.470 -1.194
201606 -1.072 101.688 -1.422
201609 -0.321 101.861 -0.425
201612 -0.665 101.863 -0.881
201703 -0.649 102.862 -0.851
201706 -0.413 103.349 -0.539
201709 -0.676 104.136 -0.876
201712 1.047 104.011 1.358
201803 -0.539 105.290 -0.691
201806 -0.473 106.317 -0.600
201809 0.783 106.507 0.992
201812 -0.249 105.998 -0.317
201903 -0.444 107.251 -0.559
201906 -0.311 108.070 -0.388
201909 -0.221 108.329 -0.275
201912 -0.225 108.420 -0.280
202003 -0.374 108.902 -0.463
202006 -0.220 108.767 -0.273
202009 -0.096 109.815 -0.118
202012 -0.193 109.897 -0.237
202103 -0.215 111.754 -0.260
202106 0.114 114.631 0.134
202109 -0.041 115.734 -0.048
202112 -0.108 117.630 -0.124
202203 -0.120 121.301 -0.133
202206 -0.150 125.017 -0.162
202209 -0.189 125.227 -0.204
202212 -0.052 125.222 -0.056
202303 -0.053 127.348 -0.056
202306 0.053 128.729 0.056
202309 -0.082 129.860 -0.085
202312 0.035 129.419 0.036
202403 0.045 131.776 0.046
202406 -0.048 132.554 -0.049
202409 0.045 133.029 0.046
202412 0.033 133.157 0.033
202503 -0.065 134.927 -0.065

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Protalix BioTherapeutics  (FRA:PBDA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Protalix BioTherapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines